感染症学雑誌第77巻第8号

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "感染症学雑誌第77巻第8号"

Transcription

1 1

2 2 µ Streptococcus pneumoniae µ S. pneumoniae µ S. pneumoniae

3 pbp β β pbp1a pbp2x pbp2b pbp mefe ermb pbp pbp1a pbp2x pbp2b pbp pbp pbp

4 pbp 2x pbp1a pbp2x pbp 2b mefe ermb pbp β pbp2x β β β µ µ pbp3 µ pbp3 ftsi β βpbp3 ftsi β pbp3 ftsi β pbp3 ftsi 3

5

6 4

7 5

8

9 et al et al et al et al β β et al et al et

10 al et al et al et al et al et al et al Streptococcus pneumoniae et al et al et al et al et al et al et al et al

11

日本化学療法学会雑誌第56巻第S-1号

日本化学療法学会雑誌第56巻第S-1号 Key words Streptococcus pneumoniae µ µ H F Cl H H N N H N F COOH O Fig.1. Sitafloxacinstructure. I γ S. pneumoniae Haemophilus influenzae Table1. Observationandtestschedule Observation/Tests Informedconsent

More information

研修コーナー

研修コーナー l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l

More information

日本化学療法学会雑誌第57巻第4号

日本化学療法学会雑誌第57巻第4号 Streptococcus pneumoniae Haemophilus influenzae β β Key words I β Enterococcus faecium Pseudomonas aeruginosa Streptococcus pneumoniae S. pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Table.

More information

日本化学療法学会雑誌第59巻第6号

日本化学療法学会雑誌第59巻第6号 P P Streptococcus pneumoniae S. pneumoniae Key words Streptococcus pneumoniae Fig. 1. Capsular swelling reaction of S. pneumoniae type 6B. Cells are stained dark blue using a methylene blue. Capsule is

More information

2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1

More information

nsg02-13/ky045059301600033210

nsg02-13/ky045059301600033210 φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W

More information

1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915

More information

第86回日本感染症学会総会学術集会後抄録(I)

第86回日本感染症学会総会学術集会後抄録(I) κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β

More information

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6

O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35

More information

取扱説明書 [プロジェクターユニット F01]

取扱説明書 [プロジェクターユニット F01] 1 2 3 4 5 6 7 8 9 10 11 12 a b c d a b c d a b c g h i d j e l f k m a b c d e f g K h J i V j k 13 l m 14 15 1 a 2 b b a 1 16 1 ab a b 2 ab a b 17 3 4 ab a b 1 2 18 1 a b 19 2 3 20 1 K 1 K 1 2 3 a b a

More information

産衛誌57-4たより.indb

産衛誌57-4たより.indb A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al

More information

172( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 2 Apr. 2002 1 19 6 2002 5 8 4 254 254 (PBP) 90 83 65 142 PBP pbp1a, pbp2x, pbp2b 121 (49%), pbp1a, pbp2x 30 (12%), pbp2x, pbp2b 16 (6%), pbp2x 61 (24%),

More information

10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1

10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1 4 16 1 10:0010 : 24 1F Annex 1! 2 15:0015 : 24 1F Annex 1!! 10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1 ! 2 10:0010 : 28 1F Annex 1 3 15:0015 : 28 1F Annex 1 4 10:3010 : 58 1F Annex 1 1 15:3015

More information

日歯雑誌(H28・8月号)別刷り/ポスターセッション とびら

日歯雑誌(H28・8月号)別刷り/ポスターセッション とびら α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α

More information

内科96巻3号★/NAI3‐1(第22回試験問題)

内科96巻3号★/NAI3‐1(第22回試験問題) µ µ α µ µ µ µ µ µ β β α γ µ Enterococcus faecalis Escherichia coli Legionella pneumophila Pseudomonas aeruginosa Streptococcus viridans α β 正解表正解記号問題 No. 正解記号問題 No. e(4.5) 26 e 1 a(1.2) 27 a 2

More information

2.2 (1967) (1997,2003) 2.2 ( ) 11

2.2 (1967) (1997,2003) 2.2 ( ) 11 ( ) 2.1 10 2.2 (1967) (1997,2003) 2.2 ( ) 11 12 ( ) 90150 (684) (887) (1099) (1361) (1605) (1707) (1854) 21(1946) 8 2.3 (1854) 13 (1997) (1854.12.23) (M8.4) (24 ) (M8.4) 70,000 3000 ( ) 7 2 3 3 (,1997)

More information

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 Feb. 2012 CLSI M100-S17benzylpenicillin PCG MIC 0.05 g/ml S. pneumoniae penicillin-susceptible S. pneumon

2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 Feb. 2012 CLSI M100-S17benzylpenicillin PCG MIC 0.05 g/ml S. pneumoniae penicillin-susceptible S. pneumon Feb. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 1 1 2008 2009 2011 10 25 2008 6 2009 4 Streptococcus pneumoniae 377 penicillin-binding protein: PBP 2004 S. pneumoniae 160 2 2 THE JAPANESE JOURNAL OF

More information

3/4/8:9 { } { } β β β α β α β β

3/4/8:9 { } { } β β β α β α β β α β : α β β α β α, [ ] [ ] V, [ ] α α β [ ] β 3/4/8:9 3/4/8:9 { } { } β β β α β α β β [] β [] β β β β α ( ( ( ( ( ( [ ] [ ] [ β ] [ α β β ] [ α ( β β ] [ α] [ ( β β ] [] α [ β β ] ( / α α [ β β ] [ ] 3

More information

ブック2

ブック2 30 1 15 1 39 43 56 43 MRSA MRSA 4 MRSA 1 4 1 16 6 2 PRSP BLNAR PCR 21 17.6 16.5 10 8.2 30 20 3 1 2 3 4 5 6 PRSP 1980 10 1 1987 PISP 1. PRSP-BLNARR R PRSP 1994 1996 PRSP 30 2000 50 PISP 40 10 15 BLPAR 1985

More information

日本目録規則1987年版改訂2版第2章図書改定案

日本目録規則1987年版改訂2版第2章図書改定案 2.0.1 2.0.2 2.0.3 2.0.4 2.0.5 2.0.6 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.2.1 2.2.2 2.2.3 2.2.4 2.4.1 2.4.2 2.4.3 2.4.4 2.5.1 2.5.2 2.5.3 2.5.4 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 ISSN 2.6.6 2.6.7 2.7.1 2.7.2 2.7.3

More information

日本化学療法学会雑誌第57巻第1号

日本化学療法学会雑誌第57巻第1号 In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli

More information

第82 回日本感染症学会総会学術集会後抄録(I)

第82 回日本感染症学会総会学術集会後抄録(I) β Aspergillus Aspergillus β in vitro in vivo α γ α γδ Streptococcus suis S. suis Chlamydia trachomatis C. trachomatis C. trachomatis C. trachomatis Chlamydia Helicobacter pylori H. pylori H. pylori H.

More information

MI( MI() 100% 100% 75% 75% 33% 75% 60% 40% 25% 60% 1 2 3 4 5 6 7 8 9 () 12 () () () !! 1. 2. 3. 1. 2. () () () 3-5% ex. ex. 11 ex. () ex. ex. : ex. : (insula) () () ( 2009 ) () ( ) YES! ()

More information

第14〜15回 T細胞を介する免疫系.pptx

第14〜15回 T細胞を介する免疫系.pptx MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α

More information

研修コーナー

研修コーナー l l l l l l l Department of Obstetrics and Gynecology, Fukui Medical University, Fukui l l l l l l µ l β β l α l µ µ l l l l Department of Obstetrics and Gynecology, Gifu University School of Medicine,

More information

dy = sin cos y cos () y () 1 y = sin 1 + c 1 e sin (3) y() () y() y( 0 ) = y 0 y 1 1. (1) d (1) y = f(, y) (4) i y y i+1 y i+1 = y( i + ) = y i

dy = sin cos y cos () y () 1 y = sin 1 + c 1 e sin (3) y() () y() y( 0 ) = y 0 y 1 1. (1) d (1) y = f(, y) (4) i y y i+1 y i+1 = y( i + ) = y i 007 8 8 4 1 1.1 ( ) (partial differential equation) (ordinary differential equation) 1 dy = f(, y) (1) 1 1 y() (1) y() (, y) 1 dy = sin cos y cos () y () 1 y = sin 1 + c 1 e sin (3) 1 1 5 y() () y() y(

More information

untitled

untitled 1309 06 06 020306026ァ8 BO06EIO08 6ム8 A04 フ6セ4, 18: 119-131, 2006 ゙03 ゙6セ4 メ フ09 ヌ6セ4 ヌ 01036ァ80409 07020600060203086 506 020607 02 06 0707apple020ク70109 070208046ァ80ケ0 02080ク7 apple07000ク700080706fi02080202080ク7

More information

nsg04-28/ky208684356100043077

nsg04-28/ky208684356100043077 δ!!! μ μ μ γ UBE3A Ube3a Ube3a δ !!!! α α α α α α α α α α μ μ α β α β β !!!!!!!! μ! Suncus murinus μ Ω! π μ Ω in vivo! μ μ μ!!! ! in situ! in vivo δ δ !!!!!!!!!! ! in vivo Orexin-Arch Orexin-Arch !!

More information

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性 2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4

More information

3 4 6 7 8 9 10 12 14 2 3

3 4 6 7 8 9 10 12 14 2 3 3 4 6 7 8 9 10 12 14 2 3 POINT 4 5 3053 1323 4 7 6 1 1 4 7 Yamada N. et al : Int J Cardiol. 98, 409-411, 2005 6 7 POINT 0 20 40 60 80 100 60 80 Ota M. et al: Heart Vessels. 17, 7-11,2002 40 60 20 50 15

More information

日本分子第5巻2号_15特別講演・シンポジウム.indd

日本分子第5巻2号_15特別講演・シンポジウム.indd 25 JSMI Report JSMI Report 26 41 JSMI Report JSMI Report 42 JSMI Report 54 55 JSMI Report JSMI Report 56 57 JSMI Report JSMI Report 58 59 JSMI Report JSMI Report 60 61 JSMI Report β JSMI Report 62 63 JSMI

More information

2

2 C o r n e l i u s The Science of E m o t i o n I z a r d The Psychology of Emotions Rusalova et al. Schwartz et al E M G 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 The science of emotion The psychology

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1

THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1 June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 175 29 1 2 2 2 2 2 3 4 4 5 5 2 2 1 2 3 4 5 2014 4 15 STFX 50 mg 10% 2011 8 1 100 mg 1 1 2011 12 2013 5 226 1,186 1,089 1,069 2.11% 23/1,089 1.10% 12/1,089

More information

I II III IV V

I II III IV V I II III IV V N/m 2 640 980 50 200 290 440 2m 50 4m 100 100 150 200 290 390 590 150 340 4m 6m 8m 100 170 250 µ = E FRVβ β N/mm 2 N/mm 2 1.1 F c t.1 3 1 1.1 1.1 2 2 2 2 F F b F s F c F t F b F s 3 3 3

More information

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

More information

600mg 600mg CTD 2 2.5 2.5 Page 3 2.5...7 2.5.1...7 2.5.2...27 2.5.3...28 2.5.4...42 2.5.5...55 2.5.6...79 2.5.7...97 2.5 Page 5 73 67 31 48 48A 102 104 105 106 ALP ALT(GPT) AST(GOT) AUC AUEC BID BUN

More information

日本化学療法学会雑誌第50巻第6号

日本化学療法学会雑誌第50巻第6号 13 11 30 14 4 22 Streptococcus pneumoniae Haemophilus influenzae amoxicillin AMPC cefditoren pivoxil CDTR AMPC 50 mg kg day CDTR 9mg kg day CDTR 18 mg kg day S. pneumoniae H. influenzae 8 17 25 1 25 S.

More information

日本化学療法学会雑誌第61巻第6号

日本化学療法学会雑誌第61巻第6号 β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae

More information

1 3 1.1.......................... 3 1............................... 3 1.3....................... 5 1.4.......................... 6 1.5........................ 7 8.1......................... 8..............................

More information

_02三浦.indd

_02三浦.indd 36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut

More information

数学概論I

数学概論I {a n } M >0 s.t. a n 5 M for n =1, 2,... lim n a n = α ε =1 N s.t. a n α < 1 for n > N. n > N a n 5 a n α + α < 1+ α. M := max{ a 1,..., a N, 1+ α } a n 5 M ( n) 1 α α 1+ α t a 1 a N+1 a N+2 a 2 1 a n

More information

感染症学雑誌第80巻第6号

感染症学雑誌第80巻第6号 Streptococcus pyogenes Streptococcus Streptococcus pyogenes Streptococcus dysgalactiae equisimilis S. pyogenes S. pyogenes S. dysgalactiae equisimilis S. pyogenes S. dysgalactiae equisimilis S. pyogenes

More information

日本糖尿病学会誌第58巻第1号

日本糖尿病学会誌第58巻第1号 α β β β β β β α α β α β α l l α l μ l β l α β β Wfs1 β β l l l l μ l l μ μ l μ l Δ l μ μ l μ l l ll l l l l l l l l μ l l l l μ μ l l l l μ l l l l l l l l l l μ l l l μ l μ l l l l l l l l l μ l l l l

More information

437“ƒ

437“ƒ et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

More information

07-第4章村上英吾.indd

07-第4章村上英吾.indd 1990 1990 2007 2000 2007 9 3 46 1 2 1960 1 1984 60 3 1970 4 2000 2003 2009 2011 12007 2 2007 12 25 2 1 2007 10 19 1 5 2007 12 11 3 Bradshaw, J., et. al., 2008. 41982 47 2010 5 2011 2004 2004 1994 5 2009

More information

cit_5.vp

cit_5.vp 132007 000606020902010608 0606ィャ49, 015 0903090208 FtsZ 06 000606020806010305 07 0908080603040607 08 06. 03. 00ィィ03ィェ07ィコ0609, 05. 01. 090608010902ィェィィィョ09 06. 03. 00ィィ03ィェ07ィコ0609, 05. 01. 090608010902ィェィィィョ09

More information

EPSON LP-8900ユーザーズガイド

EPSON LP-8900ユーザーズガイド 3 4 5 6 7 8 abc ade w p s 9 10 s s 11 p 12 p 13 14 p s 15 p s A B 16 w 17 C p 18 D E F 19 p w G H 20 A B 21 C s p D 22 E s p w 23 w w s 24 p w s 25 w 26 p p 27 w p s 28 w p 29 w p s 30 p s 31 A s B 32

More information

スライド 1

スライド 1 ファイザー KK 社内勉強会 肺炎球菌ワクチンと マクロライド耐性マイコプラズマ 肺炎球菌はどのように進化していくのか? マクロライド耐性マイコプラズマは何故発生するか? 東栄病院小児科菊田英明平成 28 年 9 月 8 日 肺炎球菌 : Streptococcus pneumoniae 肺炎球菌はどのように進化していくのか? 莢膜による免疫機構の回避 肺炎球菌 莢膜 肺炎球菌 莢膜 補体 抗体 食細胞

More information

1 Edward Waring Lagrange n {(x i, y i )} n i=1 x i p i p i (x j ) = δ ij P (x) = p i p i (x) = n y i p i (x) (1) i=1 n j=1 j i x x j x i x j (2) Runge

1 Edward Waring Lagrange n {(x i, y i )} n i=1 x i p i p i (x j ) = δ ij P (x) = p i p i (x) = n y i p i (x) (1) i=1 n j=1 j i x x j x i x j (2) Runge Edwrd Wring Lgrnge n {(x i, y i )} n x i p i p i (x j ) = δ ij P (x) = p i p i (x) = n y i p i (x) () n j= x x j x i x j (2) Runge [] [2] = ξ 0 < ξ < ξ n = b [, b] [ξ i, ξ i ] y = /( + 25x 2 ) 5 2,, 0,,

More information

日本糖尿病学会誌第58巻第3号

日本糖尿病学会誌第58巻第3号 l l μ l l l l l μ l l l l μ l l l l μ l l l l l l l l l l l l l μ l l l l μ Δ l l l μ Δ μ l l l l μ l l μ l l l l l l l l μ l l l l l μ l l l l l l l l μ l μ l l l l l l l l l l l l μ l l l l β l l l μ

More information

THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 azithromycin AZM, 500 mg 37.0 C communityacquired pneumonia; CAP C C-reactive protein; CRP 9

THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 azithromycin AZM, 500 mg 37.0 C communityacquired pneumonia; CAP C C-reactive protein; CRP 9 June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 193 47 1 1 1 1 3 3 4 1 5 6 1 2 5 5 1 2 4 1 6 1 3 7 2 1 1 2 3 4 5 6 7 2014 4 14 azithromycin; AZM 15 community-acquired pneumonia; CAP AZM A-DROP CAP AZM

More information

スライド 1

スライド 1 e-japan -2004 1 Integrated Healthcare Network (IHN) e-icusentara Sentara Healthcare T C I H A H I 0 5 0 3 T C I H A H I 2 10 6 1 0 1935 40 45 50 55 60 65 70 75 80 85 90 95 2000 K. Matsuoka et al.

More information

28_04_斎藤正章.indd

28_04_斎藤正章.indd 37 2820103743,. 282010.3743 純 粋 持 株 会 社 における 経 営 管 理 上 の 課 題 1 2 ABSTR ACT...... 1 2 1 38 2 1 1 3 2 1 1 4 5 6 7 8 1 2 1 1992.269 39 1 1 1 2 9 1 2 3 123 13 2 1995.268 40,.1995 3 10, et al.1995 2 1950 2

More information

: : 2001227 : 2

: : 2001227 : 2 : : 2001227 : 2 mg/100gmg/100g mg/100g 3 10/102006 12/05 2/19, 2007 Zn 63 98 4 10% 5 Ramesh et al. 2004 6 Connoly et al. 2002 A IRT 7 8 2.11mg/100g143%56% 9 10 Alaria praelonga 11 2 12 13 14 15 16 1 1

More information

untitled

untitled Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium

More information

untitled

untitled c OR 21 OR 1. 21 21 IoT OR OR OR 260 8672 1 8 1 OR 2. 2.1 public health [1] communicable (infectious) diseases vehicle burden HIV/AIDS (SARS) 258 60 Copyright c by ORSJ. Unauthorized reproduction of this

More information

idwr2008_21

idwr2008_21 VanC 521 0.63 0.24 2.12 2.27 1.07 0.98 1.75 0.70 27.24 0.76 1.16 0.35 1.26 0.71 2SD 1SD 1SD 2SD A SD 0.21 0.58 3.02 7.02 1.89 0.70 0.20 0.72 0.11 0.37 0.43 0.04 0.79 0.39 5515 6.19 Streptococcus pyogenes

More information

2

2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 10mSv 15 16 17 4.46 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 3.8 2.07 2.91 1.37 2.3 1.31 1.84 1.56 1.2 1.33 2.03 0.5 1000 4000mSv 1000 4000mSv Preston et al. Radiat Res 168: 1 64,

More information

会津若松市民の運動行動における変化ステージの評価

会津若松市民の運動行動における変化ステージの評価 2 Bandura1977 2000 Bandura 50 36 3 4 MarcusSimkin1993 2002 6 6 6 6 1995 2000.81 1998 1995 2000.91 2000 5 .65 1986.83 Marcus et al1992 2002 Pros.81 Cons.80 Pros Cons Pros Cons 6 7 8 9 10 11 12 13 5 Tukey

More information

1. - - - 2 - - 3 - - 4 - 1 Muser KT, Bond GR, Drake RE, et al(1998). Model of community care for severe mental illness: A review of research on case management. Schizophrenia Bulletin, 24(1): 33-74. -

More information

主要耐性菌の概要.ppt

主要耐性菌の概要.ppt 1. 2. KPC- 3. NDM-1-β- 4. CTX-M-15ST131 CTX-M-9CTX-M-14 5. Oct. 1, 2010 1SSI 2.2008 3Acinetobacter 4 MRSA PRSP GP VRE MR-S. aureus (erm) PRGBS MR-S. pneum (mefe) MDR-TB XDR-TB 1970 GN 1980 ESBL 1990 EM-R

More information

プラズマ核融合学会誌1月【83-2】/講座2-3

プラズマ核融合学会誌1月【83-2】/講座2-3 2.3 Plasma Flow Measurements Spectroscopic Methods KADO Shinichiro author s e-mail: kado@q.t.u-tokyo.ac.jp Czerny-Turner GN: grating normalmn: mount normalfn: facet normal. f L L Fig. 3 μ μ in-situ μ

More information

idwr2015_24

idwr2015_24 S. boydii S. sonnei K. pneumoniae E. aerogenes E. coli E. cloacae E. aerogenes K. pneumoniae 5 2.40 0.19 0.76 1. 1. 0.34 0.61 0.51 0.62 0.37 0.45 1.49 2SD 1SD 1SD 2SD A SD 0.17 0.77 55 1.22 4. 3.64 7.

More information

XV-Z10000(J)Ł\1-4.p65

XV-Z10000(J)Ł\1-4.p65 http://www.sharp.co.jp/ 4 2-JW age 2 2..5, :42 2 age 2 2..5, :44 3 age 3 2..5, :44 4 2..5, :44 age 4 5 2..5, :44 age 5 6 2..5, :44 age 6 7 2..5, :44 age 7 8 age 8 2..5, :45 75 76 9 age 9 2..5, :45 4 4

More information